MFAP4 is a novel prognostic biomarker in glioma correlating with immunotherapy resistance and ferroptosis

MFAP4 is a novel prognostic biomarker in glioma correlating with immunotherapy resistance and ferroptosis

BackgroundGlioma, an aggressive brain tumor, poses a challenge in understanding the mechanisms of treatment resistance, despite promising results from immunotherapy.MethodsGenes associated with immunotherapy resistance were identified by analyzing The Cancer Genome Atlas (TCGA), the Chinese Glioma G...

Full description

Bibliographic Details
Main Authors: Yuanhao Lv, Ying Gao, Wenyu Di, Zhaoyi Li, Yashen Shi, Tianyuan Hou, Yiyang Chen, Jiaqi Tian, Miaoming Xu, Wei Su, Min Zhang, Jiateng Zhong
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Pharmacology
Subjects:
MFAP4
prognosis
biomarker
immunotherapy
gliomas
ferroptosis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1551863/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1551863/full

Similar Items